Price for prescription drugs subject to the Medicare Drug Price Negotiation Program established.
HF5156 would create a new Minnesota law governing the price of certain prescription drugs that are subject to the federal Medicare Drug Price Negotiation Program. The bill defines a “maximum fair price” by reference to the price set by the U.S. Department of Health and Human Services and bars manufacturers from accepting payment above that amount for covered drugs sold to Minnesota residents, whether dispensed in person, by mail, or through other means, except for applicable pharmacy dispensing and provider administration fees.
The bill also requires health plans and pharmacy benefit managers to reimburse pharmacies at no less than the maximum fair price or NADAC, whichever is greater, plus any dispensing fee. In addition, it authorizes the Minnesota Prescription Drug Affordability Board to request detailed financial information from health plans and PBMs about fees, rebates, and final payment amounts for these drugs, and it prohibits manufacturers from withdrawing a referenced drug from the Minnesota market to evade the pricing limits without advance written notice to the commissioner of health.
HF5156 would add a new section to Minnesota Statutes chapter 62Q and would directly regulate pricing, reimbursement, and market withdrawal practices for prescription drugs covered by the federal Medicare drug price negotiation framework. It would affect drug manufacturers, health plans, pharmacy benefit managers, pharmacies, and the state Prescription Drug Affordability Board by imposing price ceilings, reimbursement floors, disclosure obligations, and enforcement authority. The bill also creates a civil penalty for improper withdrawal of a referenced drug from sale or distribution in Minnesota, with penalties tied to either $100,000 or the annual savings associated with the drug, whichever is greater. The section would take effect January 1, 2027.
Based on the bill text and available context, the measure appears to be framed as a consumer-cost and affordability bill, with sponsors from the House majority coalition and no recorded votes or committee testimony indicating organized opposition in the provided materials. The overall sentiment is likely supportive among proponents of prescription drug price controls and transparency, especially those focused on lowering out-of-pocket and systemwide drug costs. Because no committee transcript or vote history is available, there is no documented public debate in the record provided to show a broader split.
The main points of contention likely involve the bill’s intervention in drug pricing and reimbursement, especially the requirement that manufacturers, health plans, and pharmacy benefit managers adhere to state-enforced price floors and disclosure rules tied to federal negotiated prices. Manufacturers may object to the prohibition on charging above the maximum fair price and to the penalty for withdrawing drugs from the state market, while health plans and PBMs may resist the mandated reimbursement standards and financial reporting requirements. Supporters would likely emphasize affordability, transparency, and preventing market manipulation, while critics may argue the bill could affect access, contracting flexibility, or administrative burden.